Kathleen P. Gallagher
Chief Executive Officer and President, Director · Atrium Therapeutics, Inc.
IndividualSelling only
- 2025
- Sep 22, 2026
- 4
Other insiders active in the same sector
No other insider has filed at Kathleen P. Gallagher's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Mozart Aggregator II LP - $579.20M in MDLN purchases and sales in the last 12 months
- TC Group VII S1, L.L.C. - $554.95M in MDLN purchases and sales in the last 12 months
- BERKSHIRE HATHAWAY INC - $473.67M in DVA purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $430.69M in PBLS purchases and sales in the last 12 months
- Fairmount Funds Management LLC - $399.66M in SYRE purchases and sales in the last 12 months
- Paul R. Vigano - $371.84M in AVAH purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Kathleen P. Gallagher?
Kathleen P. Gallagher is a corporate insider, tracked as Chief Executive Officer and President, Director of Atrium Therapeutics, Inc. (RNA). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Kathleen P. Gallagher submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Kathleen P. Gallagher been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($9K) across all tracked filings.
